Center for HIV/AIDS Vaccine Immunology (CHAVI)

Document Type:	Grants Notice
Funding Opportunity Number:	RFA-AI-04-051
Posted Date:	Oct 05, 2004
Original Due Date for Applications:	Feb 23, 2005
Current Due Date for Applications:	Feb 23, 2005
Archive Date:	Mar 25, 2005
Funding Instrument Type:	Cooperative Agreement
Category of Funding Activity:	Health
Expected Number of Awards:	1
Estimated Total Program Funding:	$14,900,000.00
Award Ceiling:	none
Award Floor:	none
CFDA Number:	93.855 -- Allergy, Immunology and Transplantation Research 93.855 -- Allergy, Immunology and Transplantation Research
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education

Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education

For profit organizations other than small businesses

Small businesses

Public and State controlled institutions of higher education

Private institutions of higher education

State governments

County governments

City or township governments

Special district governments

Independent school districts

Native American tribal governments (Federally recognized)

Public housing authorities/Indian housing authorities

Native American tribal organizations (other than Federally recognized tribal governments)

Others (see text field entitled "Additional Information on Eligibility" for clarification)

Additional Information on Eligibility:

Eligible agencies of the Federal Government are eligible to apply.
Foreign Institutions are not eligible however foreign collaborations are encouraged.

Agency Name

Description

NIAID seeks to establish a Center for HIV/AIDS Vaccine Immunology (CHAVI) that will support intensive and highly collaborative projects addressing key immunological roadblocks to the discovery and development of a safe and effective HIV vaccine as defined by NIAID and identified by the Global HIV Vaccine Enterprise. Over the 7-year project period the research to be designed and conducted by CHAVI will address: (1) the elucidation of (a) early immunologic and virologic events after HIV-1 infection in humans, and/or (b) immune correlates for protection in animal models; (2) the systematic design and evaluation of immunogens and adjuvants eliciting persistent mucosal and/or systemic immune responses; and (3) the evaluation of vaccine candidates in early phase clinical trials. First year funding will support a CHAVI Director and the awardee institution for (1) the further development and initial implementation of a Scientific Agenda and Strategic Plan for !
all CHAVI activities; (2) the Management and Operations resources to coordinate and manage the entire range of CHAVI activities; (3) research, to be undertaken by the CHAVI Director and investigators in the CHAVI Scientific Leadership Group, focusing on: elucidation of early immunologic and virologic events after HIV infection, and/or elucidation of correlates of immune protection in non-human primate models; as well as initiating the systematic evaluation of vaccine candidates and immunization strategies to enhance mucosal immunity, potency, antigen presentation and immunogenicity; and (4) the development of scientific resources and facilities essential to implement the Scientific Agenda. Expanded funding in the second and subsequent years will support additional research and additional investigators to fully implement the CHAVI Scientific Agenda.

Link to Full Announcement

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-04-051.html

If you have difficulty accessing the full announcement electronically, please contact:

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster NIH OER Webmaster

• HHS NIH listed by [Posted Date]
• HHS Agencywide listed by [Posted Date]